Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis

Adel Shahnam, Zainab Ridha, Michael D. Wiese, Ganessan Kichenadasse, Michael Joseph Sorich

    Research output: Contribution to journalReview articlepeer-review

    15 Citations (Scopus)


    Aims: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype. Conclusion: ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcome.

    Original languageEnglish
    Pages (from-to)1725-1732
    Number of pages8
    Issue number15
    Publication statusPublished - Oct 2016


    • colorectal neoplasm
    • ERCC1
    • ERCC2
    • GSTM1
    • GSTP1
    • meta-analysis
    • oxaliplatin
    • pharmacogenetic
    • XRCC1


    Dive into the research topics of 'Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: A meta-analysis'. Together they form a unique fingerprint.

    Cite this